论文部分内容阅读
目的:分析和研究前列地尔联合坎地沙坦治疗糖尿病肾病的临床疗效。方法:选取我院2012年8月~2014年3月住院治疗糖尿病肾病患者92例,按治疗方法不同将其分为对照组与观察组,每组患者各有46例。两组患者均给予控制血糖治疗,对照组患者在此基础上加用坎地沙坦治疗;观察组在对照组治疗基础上加用前列地尔治疗,将两组患者治疗2周后的疗效进行比较。结果:两组患者治疗效果相比:观察组高于对照组P<0.05。两组患者治疗后24小时尿蛋白检测值相比:观察组优于对照组P<0.05。结论:将前列地尔与坎地沙坦将联合应用于糖尿病肾病患者治疗中,能够有效改善患者肾功能,减少尿蛋白含量,对提高治疗效果具有重要作用。
Objective: To analyze and study the clinical efficacy of alprostadil combined with candesartan in the treatment of diabetic nephropathy. Methods: A total of 92 patients with diabetic nephropathy hospitalized from August 2012 to March 2014 in our hospital were selected. They were divided into control group and observation group according to different treatment methods, 46 cases in each group. Two groups of patients were given control of blood glucose treatment, patients in the control group on this basis plus candesartan treatment; observation group in the control group based on the treatment with alprostadil treatment, the two groups of patients after 2 weeks of treatment efficacy Compare Results: Compared with the treatment effect of the two groups: the observation group was higher than the control group (P <0.05). The urinary protein in 24 hours after treatment in both groups was significantly higher than that in control group (P <0.05). Conclusion: The combination of alprostadil and candesartan in the treatment of patients with diabetic nephropathy can effectively improve renal function and reduce urinary protein content, which has an important role in improving the therapeutic effect.